Is GlaxoSmithKline plc A Super Income Stock?

Does GlaxoSmithKline plc (LON: GSK) have the right credentials to be classed as a very attractive income play?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) continues to deliver impressive results and make encouraging progress with its drug pipeline. Indeed, the strong performance from the company has been reflected in a share price that has easily outperformed the FTSE 100 over the last year, with shares up 15% versus 7% for the wider index.

However, does this mean that GlaxoSmithKline’s attraction as an income play has diminished? Or is it still a super income stock?

Since it offers the 12th best yield in the FTSE 100, GlaxoSmithKline is clearly still an attractive income play. With a yield of 4.6%, it easily beats the FTSE 100 yield of 3.5% and offers a significantly better return than is available in savings accounts while interest rates remain at historic lows.

However, GlaxoSmithKline’s real attraction as an income stock can best be seen in its dividend per share growth rate. Indeed, dividends per share have grown at an annualised rate of 6.3% over the last four years. Even when inflation was at its highest, GlaxoSmithKline’s dividend per share growth rate still beat it.

This bodes well for the future and, furthermore, GlaxoSmithKline is forecast to increase dividends per share by 5.1% per annum over the next two years. Although less than in the last few years, this rate of growth is still highly impressive and shows that the company is continuing to perform strongly.

In addition, with the company paying out 70% of profits as dividends in 2013, there appears to be some scope for this proportion to increase. In other words, while GlaxoSmithKline is investing heavily in its research and development capabilities and needs a certain amount of profit to be retained each year to do this, it could afford to pay out a slightly higher proportion of profit as dividends than it currently is doing. The effect of this would be to make GlaxoSmithKline an even more attractive income play.

Trading on a price to earnings (P/E) ratio of 15.1, GlaxoSmithKline cannot be described as ‘cheap’ — especially when the FTSE 100 is trading on a P/E of 13.5. However, its attractive yield, strong dividend growth rate and the potential to increase the proportion of profit paid as dividends mean that it remains a super income stock.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter owns shares of GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

2 mouthwatering FTSE growth stocks I’d buy and hold for 10 years

Growth stocks purchased today could be the gateway to many years of capital growth and returns. Here are two picks…

Read more »

Investing Articles

Can the IAG share price really be as dirt cheap as it looks?

While most shares have recovered since the Covid days, the IAG share price is staying stuck to rock bottom. Surely…

Read more »

Investing Articles

BAE Systems shares are flying! Have I missed the boat?

Sumayya Mansoor looks into whether or not BAE Systems shares are still a good buy for her portfolio after the…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

1 heavyweight FTSE 100 share I’d buy as London retakes its crown

Some Footsie firms are extremely large, but that doesn't mean they couldn't get even bigger. Here's one such FTSE 100…

Read more »

Investing Articles

I’d buy 5,127 National Grid shares to generate £250 of monthly passive income

With a dividend yield of 6.5%, Muhammad Cheema takes a look at how National Grid shares can generate a healthy…

Read more »

Investing Articles

The FTSE 100’s newest member looks like a no-brainer to me!

This Fool explains why she sees the newest member of the FTSE 100 as a great opportunity after its recent…

Read more »

Investing Articles

Empty Stocks and Shares ISA? Here’s how I’d start earning a second income from scratch

Like the thought of earning extra cash tax free? Our writer explains what he'd do to begin earning passive income…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

No savings at 25? I’d start by investing £3k in these 3 red-hot FTSE 100 shares

Harvey Jones thinks these three FTSE 100 stocks would be a great way to kickstart a portfolio of UK shares.…

Read more »